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ABSTRACT
To report a case of iron overload secondary to xerocytosis, a rare 
disease in a teenager, diagnosed, by T2* magnetic resonance imaging. 
We report the case of a symptomatic patient with xerocytosis, a 
ferritin level of 350ng/mL and a significant cardiac iron overload. She 
was diagnosed by T2* magnetic resonance imaging and received 
chelation therapy Ektacytometric analysis confirmed the diagnosis of 
hereditary xerocytosis. Subsequent T2* magnetic resonance imaging 
demonstrated complete resolution of the iron overload in various 
organs, as a new echocardiography revealed a complete resolution 
of previous cardiac alterations. The patient remains in chelation 
therapy. Xerocytosis is a rare autosomal dominant genetic disorder 
characterized by dehydrated stomatocytosis. The patient may present 
with intense fatigue and iron overload. We suggest the regular use of 
T2* magnetic resonance imaging for the diagnosis and control of the 
response to iron chelation in xerocytosis, and we believe it can be 
used also in other hemolytic anemia requiring transfusions.
Keywords: Anemia; Iron overload; Magnetic resonance imaging; Chelation 
therapy; Case reports
RESUMO
Relatar um caso de sobrecarga de ferro secundária à xerocitose, 
uma doença rara, em uma adolescente, diagnosticada por meio 
de ressonância magnética em T2*. Relatamos o caso de uma 
paciente sintomática com xerocitose, nível de ferritina de 350ng/mL 
e sobrecarga de ferro cardíaca significativa. Ela foi diagnosticada 
por ressonância magnética em T2* e recebeu terapia de quelação. 
Análise por ectacitometria confirmou o diagnóstico de xerocitose 
hereditária. Na sequência, a ressonância magnética em T2* demonstrou 
resolução completa da sobrecarga de ferro em vários órgãos e 
novo ecocardiograma revelou resolução completa das alterações 
cardíacas anteriores. A paciente permanece em terapia de quelação. 
Xerocitose é uma desordem genética autossômica dominante rara, 
caracterizada por estomatocitose desidratada. O paciente pode 
apresentar fadiga intensa e sobrecarga de ferro. Sugerimos o uso 
regular de ressonância magnética em T2* para o diagnóstico e 
controle da resposta à quelação de ferro em xerocitose e acreditamos 
que o exame pode ser útil também em outras anemias hemolíticas 
que necessitam de transfusões.
Descritores: Anemia; Sobrecarga de ferro; Imagem por ressonância 
magnética; Terapia por quelação; Relatos de casos
INTRODUCTION
The hereditary form of dehydrated stomatocytosis 
(xerocytosis) is an autosomal dominant genetic disorder 
characterized by increased permeability (leaks) of the 
erythrocyte membrane potassium pump, producing 
dehydration of red blood cells. The word “stomatocytosis”, 
initially described in 1974(1,2), derives from the morphology 
of red cells in a peripheral blood smear, which resembles 
the mouth or lips. Other clinical situations may 
present this cell morphology, such as liver diseases or 
other hemolytic anemias, but these disorders present 
no change in the permeability of the erythrocyte 
membrane(3).
Xerocytosis is a rare disorder, with an incidence 
of about 1 in 50,000 live births. This is 10 to 20 times 
lower than that of hereditary spherocytosis. The 
most frequent changes in xerocytosis were mapped as 
allele alterations of chromosome 16q23-qter(3-5). It may 
529Iron overload in a teenager with xerocytosis
einstein. 2013;11(4):528-32
be considered a pleiotropic syndrome in the sense 
that the gene defect affects more than the red cell(6). 
There have been reported cases of xerocytosis with 
recurrent abortion and hydropsfetalis showing no 
response to the use of intrauterine transfusion, which is 
spontaneously resolved after birth(1,6). Another frequent 
clinical complication is an increased tendency towards 
thromboembolic events in patients with xerocytosis 
after splenectomy. The pathophysiological mechanism 
of these events has not been well-defined, but studies 
show that the erythrocytes of these individuals are more 
adherent to the endothelium. The correct diagnosis 
of these membrane disorders can modify the clinical 
course because the diagnosis of spherocytosis leads to 
splenectomy, which is not indicated in xerocytosis(1,3,5).
Laboratory analysis may reveal macrocytosis, 
elevated mean corpuscular hemoglobin concentration 
(MCHC), reticulocytosis, decreased osmotic fragility 
(increased resistance to osmotic lysis) and high levels of 
serum potassium in sequential measurements at regular 
intervals (pseudohyperkalemia)(1,4). The cells show 
greater resistance to fragmentation when submitted 
to high temperatures (46 to 49oC) when compared 
with normal erythrocytes(1). In contrast to the hyper-
hydrated form of hereditary stomatocytosis, a xerocytosis 
peripheral blood cell smear shows spikes and fewer 
stomatocytes. The number of stomatocytes present 
in xerocytosis is usually less than 10% of red cells(6). 
Ektacytometry and serial measurements of potassium 
in the same sample (showing pseudohyperkalemia) can 
confirm diagnosis(4). Osmotic gradient ektacytometry 
shows a curve that is absolutely specific (the maximum 
deformability index is normal; the “hypo-osmotic point”, 
the “hyper-osmotic point”, osmotic fragility and cell 
hydration are decreased)(5).
Clinically, xerocytosis is manifested by mild to 
moderate hemolytic anemia. The patient may present 
fatigue disproportional to the degree of anemia, which 
seems to be due to lower levels of 2,3-diphosphoglycerate 
(2,3-DPG) and elevated consumption of adenosine 
triphosphate (ATP) as a result of increased Na/K pump 
activity, which can affect oxygen affinity(3). Affected 
individuals usually present mild to moderate anemia 
and do not require frequent transfusions. Even so, 
they tend to have a significant iron overload, and the 
mechanism for this has not yet been clarified(4,5). There 
seems also to be a lack of correlation between levels 
of serum ferritin and other diagnostic results of iron 
overload, including T2* magnetic resonance imaging 
(MRI T2*) in cases with cardiac overload. This has 
been reported in studies of MRI T2* in patients with 
thalassemia major(7,8).
CASE REPORT
A 17-year-old Caucasian female patient was admitted 
to in March 1999, complaining of symptomatic anemia 
and presenting features of hemolysis, jaundice, and 
choluria, and having needed sporadic transfusions 
since childhood. She also reported a history of splenectomy 
and cholecystectomy at another treatment facility, 
as well as a liver biopsy (performed in March 1996), 
revealing hemosiderosis. She denied a similar family 
history. She had a history of neonatal ascites.
Laboratory results showed a hemoglobin concentration 
of 9.8g/dL, a mean corpuscular volume (MCV) of 113.2fl 
and a MCHC of 31.7g/dL. Hemoglobin electrophoresis 
and the glucose-6-phosphate dehydrogenase (G6PD) 
test were normal. The molecular analysis for alpha 
thalassemia showed no mutations, no unstable hemoglobin 
was detected, screening of paroxysmal nocturnal 
hemoglobinuria using the Ham test (lysis by acidified 
serum), screening of sucrose, and subsequent flow 
cytometry, were all negative. The bone marrow findings 
showed only hypercellularity in the erythroid series. The 
osmotic fragility curve suggested increased globular 
resistance. The transferrin saturation was 73% and 
the serum ferritin level was 350ng/mL. There were no 
mutations for hemochromatosis (C282Y and H63D) by 
polymerase chain reaction (PCR).
In April 2001, the patient had arrhythmia and showed 
signs of systolic heart failure, which was confirmed by 
echocardiography. She also showed signs of pulmonary 
hypertension. As the patient was symptomatic, treatment 
with aldactone (25mg/day), amiodarone (200mg/day) and 
digoxin (0.25mg/day, with control of serum in regular 
doses) was initiated with good response. Blood collected 
after the heart failure episode showed thrombocytosis, 
which was attributed to the previous splenectomy.
In April 2005, nearly 4 years after the onset of the 
cardiac symptoms and specific treatment for heart 
insufficiency, MRI T2* was requested for the quantification 
of iron deposits in the heart, liver and pancreas. The 
indices were: heart, 6.5ms; liver, 6.7ms (4.46mg Fe/g 
liver); and pancreas, 9.1ms, with positive results for iron 
overload in the heart, liver (Figure 1) and pancreas and a 
serum ferritin level of 267ng/mL.
Chelation with deferiprone (3,500mg/day) was 
introduced orally in combination with subcutaneous 
deferoxamine (2.0g/day) for periods of 10 hours a 
day by infusion pump. The patient was intolerant to 
iron chelation, presenting urticarial, erythematous, and 
pruritic reactions at the site of deferoxamine application 
(local hypersensibility). The iron chelation therapy was 
temporarily suspended and was reintroduced only 1 
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month later with good tolerance, using deferoxamine 
(2.0g/day) alone by subcutaneous application on alternating 
days. The serum ferritin dosage during the resumption 
of deferoxamine use was 240ng/mL.
The patient remained without an etiologic diagnosis. The 
clinical picture of hemolytic anemia, hemochromatosis, 
and the morphological findings in peripheral blood (which 
revealed stomatocytes and acanthocytes) suggested the 
possibility of stomatocytosis. Ektacytometric analysis was 
performed, and with the possibility of xerocytosis in mind, 
serial measurements of the patient’s and her parents’ 
potassium were requested. Pseudohyperkalemia was 
found in the patient’s sample, as shown in table 1, 
confirming the diagnosis of hereditary stomatocytosis, 
dehydrated form (xerocytosis).
Control with MRI T2* was completed in February 
2006, about 8 months after chelation therapy, showing 
a reversal of the signs of liver overload (normalization 
of function) and improvements in pancreatic and cardiac 
functions (heart: 13.8ms; liver: 23.5ms; pancreas: 14ms, 
table 2). Iron chelation was continued with deferoxamine 
until April 2007, when it was supplemented and then 
replaced by deferiprone 25mg/kg orally, three times a 
day or 75mg/kg/day. Subsequent evaluation by MRI T2*, 
in April 2008, revealed a normalization of measures in 
all areas, as shown in figure 2.
Since then, MRI T2* and echocardiography have 
shown a complete resolution and recover of cardiac 
function, as shown in table 2. The patient remains in 
chelation in order to prevent new deposits of iron using 
only deferiprone.
Figure 1. Magnetic resonance exam. (A and B) Pre-treatment image took during combination therapy of iron chelators (2005); fall of myocardial T2* sequence signal, 
T2*=6.5ms*; (C and D) Image after treatment, showing no significant drop of signal, which shows normal examination for evaluation of iron overload, T2*=45ms.  
Note that the value of T2* is inversely proportional to iron overload; the lower the value, the greater the load
Table 1. Analysis of serum potassium at 0, 2, 4 and 6 hours in the patient and 
parents samples, showing pseudohyperkalemia in the patient’s samples
Time
Initial 2 hours 4 hours 6 hours
Patient 4.6 5.7 5.9 6.3
Father 4.4 4.3 4.3 4.4
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DISCUSSION
Although the mechanism responsible for the accumulation 
of iron in patients with xerocytosis is still unclear, it is 
known that patients have considerable deposits of iron 
in the heart, liver and pancreas, leading to the same 
clinical manifestations as those found in patients with 
thalassemia and sickle cell anemia with secondary 
hemochromatosis(3,4). However, the lack of correlation 
between levels of ferritin and iron accumulation can 
be even more deleterious, as the levels found are 
often low, delaying diagnosis and remedial measures, 
specifically chelation(8). 
MRI has gained acceptance as a model for quantification 
of total body iron. It has a good cost-benefit ratio, is rapidly 
performed, reproducible and noninvasive. It can be used 
in several countries, since technical standards have been 
developed enough to make the test reliable in the daily 
clinical management of various disorders that lead to the 
accumulation of iron. MRI is often used to estimate iron 
overload in the liver and heart(7-9).
Table 2. Complete recovery of cardiac iron overload, liver and pancreas as measured by MRI T2* and reflected in an improvement of cardiac function measured by 
echocardiography after chelation therapy
Measurement
Date
4/20/05 3/13/07 3/18/08 7/14/09 6/10/10
Left ventricular diastolic diameter (3.6-5.2cm) 5.2 4.8 5.2 4.8 5
Left ventricular systolic diameter (2.6-3.4cm) 3.6 2.9 2.9 3.2 3.1
Ejection fraction (>0.55%) 0.58 0.70 0.75 0.62 0.68
Left ventricular mass index (<96g/m2, female) 97 109 141 116 87
Aortic root (2.1-3.7cm) 2.8 2.9 2.7 2.9 3
Left atrium (1.9-4.0cm) 3.7 4 4.2 4.1 4.1
Right ventricule (1.0-2.6cm) 1.6 2.4 2.3 2.2 2.5
Ventricular septal (0.9-1.1cm) 0.9 1.1 1.2† 1.2 0.9
Pulmonary artery systolic pressure (<35mmHg) 26 32
Liver iron concentration (<2.2mg/g dry weight) 3.9 1.2 1.4 2.0 1.4
MRI T2* liver (>12.5ms) 6.7 23.5 20 13.7 19.5
MRI T2* heart (>20ms) 6.5 13.8 45 33.1 43.2
MRI T2* pancreas (>21ms) 9.1 14 17 NA NA
†Standard flow type pseudo normal left ventricular filling (diastolic dysfunction moderate).
NA: a myolipoma was detected in the left adrenal which impaired the pancreatic measurement in T2* MRI; RM T2*: ressônancia magnética em T2*.
Figure 2. Cytology smear of peripheral blood of the patient with stomatocytes (arrows). Leishmandye, 100 x
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Serum levels of ferritin do not correlate with cardiac 
deposits and, in the heart, intense tissue toxicity can 
be observed even without large deposits of iron(8). 
Cardiac iron cannot be measured by ferritin levels or 
hepatic iron accumulation, and conventional methods 
of cardiac evaluation do not detect changes until 
dysfunctions have already set in(7,10). The use of MRI 
T2* for the measurement of cardiac iron allows for early 
identification of patients who require iron chelation, 
even before the onset of symptoms or echocardiographic 
findings consistent with systolic dysfunction, allowing 
for a reduction in mortality related to heart failure(10,11).
MRI T2* is considered the standard procedure 
for the diagnosis of iron overload(7). It is important 
to diagnose and treat other hemolytic anemias that 
lead to iron overload, including xerocytosis, since these 
patients often present with symptoms of heart failure and 
diabetes, secondary to hemochromatosis, even without 
an elevated number of transfusions, or with elevated 
levels of ferritin still below 500ng/mL. We suggest the 
regular use of MRI T2* for the diagnosis, monitoring, 
control of the response to overload, and iron chelation 
in patients with xerocytosis, and we believe it can be used 
also in the follow-up of other hemolytic anemia requiring 
transfusions, even if sporadically. This would allow early 
diagnosis of iron overload and chelation therapy.
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